Severe Persistent Eczema in a Recipient of the Gam-COVID-Vac vaccine.
COVID-19
Sputnik V
eczema
Journal
European journal of case reports in internal medicine
ISSN: 2284-2594
Titre abrégé: Eur J Case Rep Intern Med
Pays: Italy
ID NLM: 101648453
Informations de publication
Date de publication:
2022
2022
Historique:
received:
31
10
2021
accepted:
05
12
2021
entrez:
16
2
2022
pubmed:
17
2
2022
medline:
17
2
2022
Statut:
epublish
Résumé
Since the beginning of the COVID-19 pandemic, efforts have been made to design safe and effective vaccines against SARS-CoV-2. Numerous vaccines have been designed and tested in limited clinical trials in various countries. Among them, the Sputnik V vaccine has shown a relatively safe profile and, to our knowledge, has no associated major side effects. We describe the case of a 40-year-old female healthcare worker who developed severe persistent eczematous lesions on the second day after she received the first dose of the Sputnik vaccine. The eczematous lesions were refractory to an antihistamine and persisted at the 1 month follow-up. Severe persistent eczematous lesions should be viewed as a potential side effect of vaccination with the Sputnik V vaccine. Moreover, a severe allergic reaction to a COVID-2019 vaccine may indicate the vaccine is ineffective in the recipient. Vaccination against COVID-19 may be accompanied by rare complications.Eczematous lesions can be a side effect of the Sputnik V vaccine.A severe allergic reaction to a COVID-19 vaccine may result in decreased vaccine effectiveness in the recipient.
Identifiants
pubmed: 35169571
doi: 10.12890/2022_003042
pii: 3042-1-26685-1-10-20220111
pmc: PMC8833308
doi:
Types de publication
Journal Article
Langues
eng
Pagination
003042Informations de copyright
© EFIM 2022.
Déclaration de conflit d'intérêts
Conflicts of Interests: The authors declare there are no competing interests.
Références
Sci Rep. 2021 Nov 2;11(1):21464
pubmed: 34728696
Ann Intern Med. 2021 May;174(5):694
pubmed: 33769829
MMWR Morb Mortal Wkly Rep. 2021 Jan 15;70(2):46-51
pubmed: 33444297
Lancet. 2021 Feb 20;397(10275):642-643
pubmed: 33545098
Lancet. 2021 Feb 20;397(10275):671-681
pubmed: 33545094
Lancet Reg Health Eur. 2021 Dec;11:100241
pubmed: 34746910
Lancet Reg Health Am. 2022 Feb;6:100123
pubmed: 34841388
BMC Public Health. 2003 Aug 11;3:26
pubmed: 12911836
Vaccines (Basel). 2021 Mar 05;9(3):
pubmed: 33807579
JAMA. 2020 Nov 3;324(17):1723-1724
pubmed: 33031513